Results 41 to 50 of about 405 (144)

Combate à resistência aos antibióticos : novas moléculas/estratégias em fase clínica de desenvolvimento [PDF]

, 2023
Dissertação para obtenção do grau de Mestre no Instituto Universitário Egas MonizIntrodução: A resistência antimicrobiana é a capacidade de um microrganismo impedir que um agente antimicrobiano funcione contra ele, impondo sérias limitações no tratamento
Nunes, Pedro Miguel Ascensão
core  

An Epidemiological and Pharmacokinetic-pharmacodynamic Investigation into the Impact of Carbapenem-resistant Enterobacterales [PDF]

, 2023
Background: According to the 2019 CDC Antibiotic Resistance Threats Report, more than 2.8 million antibiotic-resistant infections occur in the United States each year, leading to more than 35,000 deaths.
Clark, Justin
core   +2 more sources

Stellenwert von Piperacillin/Tazobactam bei Patienten mit Blutstrominfektionen durch Ampicillin/Sulbactam-resistente nicht-Extended-Spektrum Betalaktamase-produzierende Escherichia coli: eine retrospektive Kohortenstudie [PDF]

Bakteriämien, der kulturelle Nachweis von Bakterien im Blutkreislauf, mit zusätzlich klinischen Zeichen einer Infektion stellen ein bedeutendes Gesundheitsproblem weltweit dar.
Paulussen, Emilia
core   +1 more source

Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation

Expert Opinion on Drug Metabolism & Toxicology
Cefepime/enmetazobactam is a novel β-lactam/β-lactamase inhibitor (BL-BLI) combination with broad Gram-positive and -negative activity. Cefepime is relatively resistant to hydrolysis by AmpC, and enmetazobactam inhibits all Ambler Class A extended spectrum β-lactamases (ESBLs). Hence, the combination is resistant to hydrolysis by many ESBLs.
Christopher A Darlow, William Hope, Vineet Dubey   +2 more
openaire   +2 more sources

A Review of In Silico and In Vitro Approaches in the Fight Against Carbapenem‐Resistant Enterobacterales

Journal of Clinical Laboratory Analysis, Volume 39, Issue 9, May 2025.
This review highlights computational approaches for discovering antimicrobials against carbapenem‐resistant Enterobacterales. It outlines methods like pharmacophore modeling, molecular docking, and absorption, distribution, metabolism, and excretion–toxicity (ADMET) analysis, integrated with in vitro assays, to identify and validate potential drugs ...
Muhammad Absar, Abdul Rahman Zaidah, Amer Mahmood, Sajjad Ahmad, Hasan Ejaz, Naveed Ahmed, Nik Haszroel Hysham Nik Hashim, Chan Yean Yean   +7 more
wiley   +1 more source

P20 Evaluation of cefepime/enmetazobactam against MDR Enterobacterales [PDF]

JAC Antimicrob Resist
Abstract Background Cefepime/enmetazobactam is a fourth generation cephalosporin in combination with a novel penicillanic acid sulfone ESBL inhibitor. Cefepime is stable to AmpC β-lactamases (class C) and OXA-48-like carbapenemases (class D) whilst enmetazobactam has activity against most class A β ...
Richards, J R, Wooton, M, Ward, J R
europepmc   +2 more sources

A review of antibiotic safety in pregnancy—2025 update

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.
Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen, Victoria Madonia, Christopher M. Bland, Kayla R. Stover, Lea S. Eiland, Julia Keating, Madeline Lemmon, P. Brandon Bookstaver, as part of the Southeastern Research Group Endeavor (SERGE‐45) research network   +8 more
wiley   +1 more source

Antimicrobial Challenge in Acute Care Surgery [PDF]

, 2022
The burden of infections in acute care surgery (ACS) is huge. Surgical emergencies alone account for three million admissions per year in the United States (US) with estimated financial costs of USD 28 billion per year.
Bianchi G., Carra M. C., de'Angelis G. L., de'Angelis N., Schena C. A.   +4 more
core   +2 more sources

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review

British Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.
Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis, Andreas Papapetropoulos, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions [PDF]

[Objectives] To analyse the impact of the most clinically relevant β-lactamases and their interplay with low outer membrane permeability on the activity of cefiderocol, ceftazidime/avibactam, aztreonam/avibactam, cefepime/enmetazobactam, cefepime ...
Blanco-Martín, Tania, Alonso-García, Isaac, González-Pinto, Lucía, Outeda-García, Michelle, Guijarro-Sánchez, Paula, López-Hernández, Inmaculada, Perez-Vazquez, Maria, Aracil, Belen, López-Cerero, Lorena, Fraile-Ribot, Pablo, Oliver, Antonio, Vázquez-Ucha, Juan Carlos, Beceiro, Alejandro, Bou, Germán, Arca-Suárez, Jorge, GEMARA/SEIMC-CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT)   +15 more
core   +2 more sources